About Us

The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.

We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.

Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.

JDD reaches around 13,760 dermatology healthcare professionals and has been recognized as the official partner of the Skin of Color Update (SOCU) and the ODAC Dermatology Aesthetic and Surgical (ODAC) conferences.

The extremely current and practical editorial content of JDD results in high readership and maximum exposure among the dermatology community.

Our Mission is Excellence through Peer Review: To educate physicians, optimize patient outcomes, and disseminate key scientific information.

JDD is published by SanovaWorks.

In the News

September 22, 2025 in Atopic Dermatitis, Featured Articles, JDD Highlights, JDD in the Media, The Latest

JDD in the News: Pharmacy Deserts and Affordability Concerns in Atopic Dermatitis Care

Healio profiled a July Journal of Drugs in Dermatology study on the affordability of dermatologist-recommended skincare products for atopic dermatitis. The study, “Socioeconomic Disparities in Gentle Skin Care Access for…
Read More
August 18, 2025 in Featured Articles, JDD Highlights, JDD in the Media, Skincare, The Latest

JDD in the News: Perceived Dermatologic Side Effects of Cancer Treatments

Several media outlets covered an August Journal of Drugs in Dermatology survey on the perceived dermatologic side effects of cancer treatments and how those perceptions could impact a person’s decision…
Read More
June 23, 2025 in JDD Highlights, JDD in the Media, Skin Cancer, The Latest

Dermatology Roundup: Drug Class Effective Against Treatment-Resistant Melanoma

Researchers at NYU Langone Health and the Perlmutter Cancer Center have discovered why many patients with melanoma are resistant to current treatments and how an existing drug class is effective…
Read More
June 20, 2025 in Featured Articles, JDD Highlights, JDD in the Media, Skincare, The Latest

JDD in the News: Proposed Universal Classification System for Topical Corticosteroids 

Healio profiled a new universal classification system for topical corticosteroids that could reduce confusion across countries. The system was published in the May Journal of Drugs in Dermatology in an…
Read More
May 21, 2025 in Acne, Derm Community, Featured Articles, JDD Highlights, JDD in the Media, The Latest

JDD in the News: Upadacitinib’s Potential Cardiovascular Effects 

Upadacitinib may provide additional health benefits, including reducing the risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). That’s according to a May Journal of Drugs in Dermatology…
Read More

Editorial Board

Founder
Perry Robins, MD

Editor-in-Chief
Deborah S. Sarnoff MD